These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38676874)

  • 1. Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma.
    Sánchez Prieto I; Gutiérrez Jomarrón I; Martínez Vázquez C; Rodríguez Barquero P; Gili Herreros P; García-Suárez J
    J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38676874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.
    Rubio-Terrés C; Soria JM; Morange PE; Souto JC; Suchon P; Mateo J; Saut N; Rubio-Rodríguez D; Sala J; Gracia A; Pich S; Salas E
    Appl Health Econ Health Policy; 2015 Apr; 13(2):233-42. PubMed ID: 25652150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice.
    Rupa-Matysek J; Brzeźniakiewicz-Janus K; Gil L; Krasiński Z; Komarnicki M
    Cancer Med; 2018 Jul; 7(7):2868-2875. PubMed ID: 29761831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multilocus genetic risk scores for venous thromboembolism risk assessment.
    Soria JM; Morange PE; Vila J; Souto JC; Moyano M; Trégouët DA; Mateo J; Saut N; Salas E; Elosua R
    J Am Heart Assoc; 2014 Oct; 3(5):e001060. PubMed ID: 25341889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
    Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
    J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.
    Sanfilippo KM; Carson KR; Wang TF; Luo S; Edwin N; Kuderer N; Keller JM; Gage BF
    Res Pract Thromb Haemost; 2022 Jan; 6(1):e12634. PubMed ID: 35028491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
    Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
    Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies.
    Nemeth B; van Adrichem RA; van Hylckama Vlieg A; Bucciarelli P; Martinelli I; Baglin T; Rosendaal FR; le Cessie S; Cannegieter SC
    PLoS Med; 2015 Nov; 12(11):e1001899; discussion e1001899. PubMed ID: 26554832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma.
    Kirkizlar O; Alp Kirkizlar T; Umit EG; Asker I; Baysal M; Bas V; Gulsaran SK; Demirci U; Demir AM
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):542-547. PubMed ID: 32245743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic Risk and Calculated Whole Blood Viscosity in a Cohort of Patients With New Diagnosis of Multiple Myeloma.
    Carlisi M; Presti RL; Mancuso S; Siragusa S; Caimi G
    Clin Appl Thromb Hemost; 2024; 30():10760296231222477. PubMed ID: 38173275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP).
    Timp JF; Braekkan SK; Lijfering WM; van Hylckama Vlieg A; Hansen JB; Rosendaal FR; le Cessie S; Cannegieter SC
    PLoS Med; 2019 Oct; 16(10):e1002883. PubMed ID: 31603898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients.
    Barrett A; Quinn J; Lavin M; Thornton P; O'Donnell J; Murphy P; Glavey S
    J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
    Covut F; Ahmed R; Chawla S; Ricaurte F; Samaras CJ; Anwer F; Garcia AVM; Angelini DE; Mazzoni S; Faiman B; Valent J; Khouri J
    Br J Haematol; 2021 Jun; 193(6):1213-1219. PubMed ID: 33997961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma.
    Bastos-Oreiro M; Ortiz J; Pradillo V; Salas E; Marínez-Laperche C; Muñoz A; Buño I; Diéz-Martin JL; Soria JM; Pascual Izquierdo C
    Cancer Med; 2021 Nov; 10(21):7585-7592. PubMed ID: 34598309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models.
    Dharmavaram G; Cao S; Sundaram S; Ayyappan S; Boughan K; Gallogly M; Malek E; Metheny L; Tomlinson B; Otegbeye F; Lazarus HM; Cooper B; Fu P; de Lima M; Caimi PF
    Am J Hematol; 2020 Aug; 95(8):918-926. PubMed ID: 32311162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study.
    Bao L; Fang LJ; Xiao MY; Lu MQ; Chu B; Shi L; Gao S; Xiang QQ; Wang YT; Liu X; Ding YH; Xin Z; Chen Y; Wang MZ; Hu WK; Guo CY; Chen LY; Sun K
    Thromb Res; 2024 Apr; 236():130-135. PubMed ID: 38430904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic Risk Assessment in Patients with Lymphoid Neoplasm seen at the Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State.
    Chilaka UJ; Benedict N; Kingsley C; Clara A; Geoffery E; Chinedum E; Onyinye NP
    West Afr J Med; 2023 May; 40(5):533-540. PubMed ID: 37247203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-dimer predicts venous thromboembolism in multiple myeloma: a nested case-control study.
    Sanfilippo KM; Fiala MA; Feinberg D; Tathireddy H; Girard T; Vij R; Di Paola J; Gage BF
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102235. PubMed ID: 38193055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.